Cargando…

Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer

To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three conditions: untreated tumor, treated tumor, and tumor treated after CD4+ T cell deplet...

Descripción completa

Detalles Bibliográficos
Autores principales: Freshour, Sharon L., Chen, Timothy H.-P., Fisk, Bryan, Shen, Haolin, Mosior, Matthew, Skidmore, Zachary L., Fronick, Catrina, Bolzenius, Jennifer K., Griffith, Obi L., Arora, Vivek K., Griffith, Malachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081275/
https://www.ncbi.nlm.nih.gov/pubmed/37034778
http://dx.doi.org/10.1101/2023.03.28.534561
_version_ 1785021077720662016
author Freshour, Sharon L.
Chen, Timothy H.-P.
Fisk, Bryan
Shen, Haolin
Mosior, Matthew
Skidmore, Zachary L.
Fronick, Catrina
Bolzenius, Jennifer K.
Griffith, Obi L.
Arora, Vivek K.
Griffith, Malachi
author_facet Freshour, Sharon L.
Chen, Timothy H.-P.
Fisk, Bryan
Shen, Haolin
Mosior, Matthew
Skidmore, Zachary L.
Fronick, Catrina
Bolzenius, Jennifer K.
Griffith, Obi L.
Arora, Vivek K.
Griffith, Malachi
author_sort Freshour, Sharon L.
collection PubMed
description To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three conditions: untreated tumor, treated tumor, and tumor treated after CD4+ T cell depletion. After classifying tumor cells based on detection of somatic variants and assigning non-tumor cell types using SingleR, we performed differential expression analysis, overrepresentation analysis, and gene set enrichment analysis (GSEA) within each cell type. GSEA revealed that endothelial cells were enriched for upregulated IFN-g response genes when comparing treated cells to both untreated cells and cells treated after CD4+ T cell depletion. Functional analysis showed that knocking out IFNgR1 in endothelial cells inhibited treatment response. Together, these results indicated that IFN-g signaling in endothelial cells is a key mediator of ICB induced anti-tumor activity.
format Online
Article
Text
id pubmed-10081275
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-100812752023-04-08 Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer Freshour, Sharon L. Chen, Timothy H.-P. Fisk, Bryan Shen, Haolin Mosior, Matthew Skidmore, Zachary L. Fronick, Catrina Bolzenius, Jennifer K. Griffith, Obi L. Arora, Vivek K. Griffith, Malachi bioRxiv Article To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three conditions: untreated tumor, treated tumor, and tumor treated after CD4+ T cell depletion. After classifying tumor cells based on detection of somatic variants and assigning non-tumor cell types using SingleR, we performed differential expression analysis, overrepresentation analysis, and gene set enrichment analysis (GSEA) within each cell type. GSEA revealed that endothelial cells were enriched for upregulated IFN-g response genes when comparing treated cells to both untreated cells and cells treated after CD4+ T cell depletion. Functional analysis showed that knocking out IFNgR1 in endothelial cells inhibited treatment response. Together, these results indicated that IFN-g signaling in endothelial cells is a key mediator of ICB induced anti-tumor activity. Cold Spring Harbor Laboratory 2023-03-29 /pmc/articles/PMC10081275/ /pubmed/37034778 http://dx.doi.org/10.1101/2023.03.28.534561 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Freshour, Sharon L.
Chen, Timothy H.-P.
Fisk, Bryan
Shen, Haolin
Mosior, Matthew
Skidmore, Zachary L.
Fronick, Catrina
Bolzenius, Jennifer K.
Griffith, Obi L.
Arora, Vivek K.
Griffith, Malachi
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title_full Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title_fullStr Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title_full_unstemmed Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title_short Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer
title_sort endothelial cells are a key target of ifn-g during response to combined pd-1/ctla-4 icb treatment in a mouse model of bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081275/
https://www.ncbi.nlm.nih.gov/pubmed/37034778
http://dx.doi.org/10.1101/2023.03.28.534561
work_keys_str_mv AT freshoursharonl endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT chentimothyhp endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT fiskbryan endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT shenhaolin endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT mosiormatthew endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT skidmorezacharyl endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT fronickcatrina endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT bolzeniusjenniferk endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT griffithobil endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT aroravivekk endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer
AT griffithmalachi endothelialcellsareakeytargetofifngduringresponsetocombinedpd1ctla4icbtreatmentinamousemodelofbladdercancer